The Johns Hopkins professor and new MHE editorial advisory board member lauds the effects of the Affordable Care Act but holds out for a program that “gets every human being the healthcare that every human being deserves,” in this second part of a four-part series.
Democracy is the worst form of government — except for all the others. So the saying goes.
Otis Brawley’s opinion of the Affordable Care Act is similar.
“Is the Affordable Care Act perfect? Absolutely not. It is better than almost anything I have seen so far,” Brawley said in a recent video interview with Managed Healthcare Executive® editors, Briana Contreras and Peter Wehrwein.
Brawley, a professor of oncology and epidemiology at Johns Hopkins and former chief medical and scientific officer for the American Cancer Society, recently joined the MHE’s editorial advisory board.
In a wide-ranging conversation with Contreras and Wehrwein, Brawley’s qualified endorsement of the ACA came with observations about the law’s positive effects — and pointed criticisms of its opponents.
Related: Otis Brawley’s Split Screen: Racism, Lack of Caring — But Hope in the Response
“There are a number of studies out there that demonstrate that people are not dying because of the Affordable Care Act,” Brawley said. “There are a number of studies out there that demonstrate that people are not suffering because of the Affordable Care Act. By the same token, there are studies out there that indicate that there is more death and more suffering in states that have not expanded Medicaid under the Affordable Care Act versus the states that have. All the studies are out there.”
Brawley noted that other large federal government programs, such as Social Security and Medicare, have been continually revised since they were enacted.
“The Affordable Care Act was instituted a little over 10 years ago and it has not had the opportunity to be tweaked and changes and modified because one party keeps on saying, ‘no.’”
Brawley had some barbed observations about states that haven’t expanded Medicaid. “The places have not expanded Medicaid under the Affordable Care Act— those are states that weren’t doing very well with health care to begin with. Interestingly, they are frequently red states. That is interesting conversation. Why is it states where people don’t seem to care about each other tend to be overwhelmingly Republican? That is an interesting question.”
Still, Brawley said he is not necessarily pro Affordable Care Act, and he spoke of an ideal: “I am pro some program or series of programs that gets every human being the health care that every human being deserves.” He staked out a similar position on Medicare for all: “What I am in favor of is all people having access to health care.”
Analysis Finds Brukinsa May Provide Costs Savings Over Imbruvica in CLL
April 14th 2025In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.
Read More
Rutgers Cancer Institute Reviews Guidelines for Managing Blood Cancers During Pregnancy
April 8th 2025About 6% of pregnancy-related cancers are Hodgkin lymphoma, and 5% are non-Hodgkin lymphoma. Leukemias in pregnancy are rarer, accounting for 1 in 10,000 pregnancies. The most common pregnancy-related leukemias are acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML).
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
CAR T-Cell Therapy Cuts Costs, Reduces Treatment in Mantle Cell Lymphoma
March 13th 2025In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and costs between patients receiving CAR T-cell therapy and those treated with the non-CAR T standard of care.
Read More